Drug Profile

MEB 1170

Alternative Names: MEB-1170

Latest Information Update: 04 Apr 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MEBIAS Discovery
Class Analgesics
Mechanism of Action Opioid mu receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Opioid-related disorders; Pain

Most Recent Events

29 Nov 2022 Phase-I clinical trials in Opioid-related disorders (Prevention) in USA (PO)
29 Nov 2022 Phase-I clinical trials (In volunteers) in Pain in USA (PO) (Prior to November 2022)
06 Oct 2022 The US FDA approves IND application for MEB 1170 in Pain (MEBIAS Discovery pipeline, February 2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com